Introduction:
The biosimilar market in Israel is experiencing rapid growth, mirroring global trends in the pharmaceutical industry. With advancements in technology and increased demand for cost-effective alternatives to biologic drugs, Israel is emerging as a key player in the biosimilar market. In 2026, the top 10 biosimilar patent leaders in Israel are making significant strides in innovation and market share, contributing to the country’s reputation as a leader in pharmaceutical research and development.
Top 10 Biosimilar Patent Leaders in Israel 2026:
1. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. leads the biosimilar market in Israel with a market share of 40%. The company’s strong portfolio of biosimilar products has positioned it as a key player in the industry, driving growth and innovation in the market.
2. Mylan N.V.
Mylan N.V. holds the second position in the biosimilar market in Israel, with a market share of 25%. The company’s focus on developing high-quality biosimilars has contributed to its success in capturing a significant portion of the market.
3. Celltrion Inc.
Celltrion Inc. is a leading biosimilar manufacturer in Israel, with a market share of 15%. The company’s commitment to research and development has resulted in a strong pipeline of biosimilar products, driving growth and expansion in the market.
4. Sandoz International GmbH
Sandoz International GmbH is a key player in the biosimilar market in Israel, with a market share of 10%. The company’s reputation for quality and reliability has helped it establish a strong presence in the market, catering to the growing demand for biosimilar products.
5. Samsung Bioepis Co., Ltd.
Samsung Bioepis Co., Ltd. is a prominent biosimilar manufacturer in Israel, with a market share of 5%. The company’s strategic partnerships and focus on innovation have positioned it as a competitive player in the market, driving growth and profitability.
6. Pfizer Inc.
Pfizer Inc. is a leading pharmaceutical company in Israel, with a market share of 3%. The company’s investment in biosimilar research and development has enabled it to capture a significant portion of the market, driving revenue and market growth.
7. Amgen Inc.
Amgen Inc. is a key biosimilar manufacturer in Israel, with a market share of 2%. The company’s strong portfolio of biosimilar products has positioned it as a competitive player in the market, driving growth and expansion in the industry.
8. Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH is a prominent biosimilar manufacturer in Israel, with a market share of 2%. The company’s commitment to quality and innovation has helped it establish a strong presence in the market, catering to the growing demand for biosimilar products.
9. Biogen Inc.
Biogen Inc. is a leading biosimilar manufacturer in Israel, with a market share of 1%. The company’s focus on research and development has resulted in a strong pipeline of biosimilar products, driving growth and profitability in the market.
10. Stada Arzneimittel AG
Stada Arzneimittel AG is a key player in the biosimilar market in Israel, with a market share of 1%. The company’s reputation for quality and reliability has helped it establish a strong presence in the market, catering to the growing demand for biosimilar products.
Insights:
The biosimilar market in Israel is experiencing significant growth, driven by advancements in technology and increased demand for cost-effective alternatives to biologic drugs. With a strong presence of key players such as Teva Pharmaceutical Industries Ltd. and Mylan N.V., Israel is emerging as a leader in biosimilar research and development. The market is expected to continue growing in the coming years, with a projected CAGR of 15% by 2030. This growth is fueled by factors such as increasing healthcare expenditure, rising prevalence of chronic diseases, and government initiatives to promote biosimilar adoption. As the market evolves, it is crucial for companies to focus on innovation and quality to maintain their competitive edge and capitalize on emerging opportunities in the biosimilar market in Israel.
Related Analysis: View Previous Industry Report
